Mark Rothera
2020 - Orchard Therapeutics plc
In 2020, Mark Rothera earned a total compensation of $3.2M as Former CEO at Orchard Therapeutics plc, a 26% decrease compared to previous year.
Compensation breakdown
| Option Awards | $2,432,307 |
|---|---|
| Salary | $160,236 |
| Other | $585,465 |
| Total | $3,178,008 |
Rothera received $2.4M in option awards, accounting for 77% of the total pay in 2020.
Rothera also received $160.2K in salary and $585.5K in other compensation.
Rankings
In 2020, Mark Rothera's compensation ranked 3,661st out of 13,090 executives tracked by ExecPay. In other words, Rothera earned more than 72.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,661 out of 13,090 | 72nd |
Division Manufacturing | 1,439 out of 5,624 | 74th |
Major group Chemicals And Allied Products | 542 out of 2,257 | 76th |
Industry group Drugs | 470 out of 1,957 | 76th |
Industry Biological Products, Except Diagnostic Substances | 111 out of 411 | 73rd |
Source: SEC filing on April 28, 2021.
Rothera's colleagues
We found two more compensation records of executives who worked with Mark Rothera at Orchard Therapeutics plc in 2020.